Search

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

These Guidelines were developed by the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO). The 2 societies nominated authors to write the guidelines as well as reviewers to comment on them.

Read more

Call for SWG scientific meeting proposals

The call for SWG scientific meeting proposals is closed. As part of its aim to educate and share novel research findings, EHA provides financial support for specialized working group (SWG) scientific meetings.

Read more

Major changes needed for patients to benefit from precision medicine

Precision medicine approaches the treatment of a disease via an individual’s genes, environment, and lifestyle.

Read more

EHA-THD Joint membership

We are pleased to inform that EHA and the Türk Hematoloji Derneği (THD) have joined forces and are offering you the possibility of an EHA-THD Joint Membership in 2023.

Read more

GoCART Coalition - Call for research proposals within Work Package 6: Scientific Excellence

Dear GoCART community, 

With more than 1500 CAR-T infusions registered in the EBMT registry, EHA and EBMT are proud to announce a series of scientific calls within Work Package 6: Scientific Excellence of the GoCART coalition.

Read more

EHA and PTHiT Successfully Conclude the Second Joint Virtual Mini Hematology Tutorial

EHA-PTHiT Mini Hematology Tutorial

November 15-16, 2021

Meeting chairs:

Prof G Gaidano (European Hematology Association)
Prof I Hus (Polish Society of Hematology and Transfusion)
Prof T Robak (Polish Society of Hematology and Transfusion) 
After a successful mini Tutorial in April 2021, EHA and PTHiT decided to…

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more